Browse drug registration pathways, regulators, CTD dossier expectations, review procedures, holder duties, and post-approval obligations by country.
Public pages show drug registration overviews; during the limited-time free period, sign in or register to view complete pathways.
Drug registration routes in the same region often share CTD structure, local holder, GMP/CPP, label-language, and post-approval patterns. Start with the regional pattern, then open the country page for differences.
Typical flow: local holder or agent, CTD/eCTD, CPP/GMP, label-language work, and pharmacovigilance setup. LATAM markets often require Spanish/Portuguese localization and may focus on BE or clinical bridging.
Typical flow: local MAH/agent, CTD or ASEAN CTD, GMP/CPP, samples/testing, and label-language checks. ASEAN markets share dossier logic; China, Japan, and Korea have heavier local clinical and administrative requirements.
Typical flow: EU CTD, centralized/MRP/DCP/national route, QP/PV system, SmPC/PIL, and local languages. UK, Switzerland, and other non-EU markets require separate holders and filing routes.
Typical flow: local agent or holder, CTD, CPP/GMP, legalization, Arabic labeling, and local pharmacovigilance contact. GCC markets can reference one another but still keep local submission and fee steps.
6 countries
Typical flow: EU CTD, centralized/MRP/DCP/national route, QP/PV system, SmPC/PIL, and local languages. UK, Switzerland, and other non-EU markets require separate holders and filing routes.
Market Overview Market profile: EU pharmaceutical regulation combines EMA, the European Commission, and national competent authorities. A centralised authorisation can cover EU Mem...
Updated: 2026-05-04
Market Overview Market profile: Russia and EAEU medicine registration involves the interface between national pathways and EAEU unified rules. Geopolitical, sanctions, payment, and...
Updated: 2026-05-04
Market Overview Market profile: Switzerland is a highvalue medicine market with rigorous Swissmedic review. Marketing authorisation and BAG/reimbursement pricing are separate steps...
Updated: 2026-05-04
Market Overview Market profile: Turkey is shaped by localisation policy, external reference pricing, reimbursement, and import controls. Local MAH structure is critical. Regulatory...
Updated: 2026-05-04
Market Overview Market profile: Ukraine pharmaceutical registration is affected by war, supply chain, import, payment, and regulator capacity factors. Safety and compliance risk mu...
Updated: 2026-05-04
Market Overview Market profile: After Brexit, medicines are authorised by MHRA, while NHS, NICE, pricing, and reimbursement determine commercial access. Regulatory maturity: High....
Updated: 2026-05-04
